Skip to main content
Addgene

CAV1-K*R-mEGFP
(Plasmid #27766)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 27766 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pmEGFP-N1
  • Backbone manufacturer
    J. Lippincott-Schwartz
  • Backbone size w/o insert (bp) 4695
  • Vector type
    Mammalian Expression
  • Selectable markers
    Neomycin (select with G418)

Growth in Bacteria

  • Bacterial Resistance(s)
    Kanamycin, 50 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    caveolin-1, lysine null mutant
  • Alt name
    CAV1
  • Alt name
    cav-1
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    545
  • Mutation
    All lysines mutated to arginines (K*R)
  • GenBank ID
    NM_001753
  • Entrez Gene
    CAV1 (a.k.a. BSCL3, CGL3, LCCNS, MSTP085, PPH3, VIP21)
  • Tag / Fusion Protein
    • monomeric EGFP (C terminal on backbone)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site HindIII (not destroyed)
  • 3′ cloning site BamHI (not destroyed)
  • 5′ sequencing primer CMV Foward
  • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

The mutant CAV1-K*R cannot be ubiquitinated as all lysines are mutated to arginines.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    CAV1-K*R-mEGFP was a gift from Ari Helenius (Addgene plasmid # 27766 ; http://n2t.net/addgene:27766 ; RRID:Addgene_27766)
  • For your References section:

    Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. Hayer A, Stoeber M, Ritz D, Engel S, Meyer HH, Helenius A. J Cell Biol. 2010 Nov 1. 191(3):615-29. 10.1083/jcb.201003086 PubMed 21041450